Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases
Language English Country France Media print-electronic
Document type Journal Article, Review
PubMed
31404862
DOI
10.1016/j.ejmech.2019.111569
PII: S0223-5234(19)30699-3
Knihovny.cz E-resources
- Keywords
- Imidazo[1,2-a]pyridine, Imidazo[1,5-a]pyridine, Imidazo[4,5-b]pyridine, Imidazo[4,5-c]pyridine, Neurodegenerative disorders, Neurological disorders, Sleeping disorders,
- MeSH
- Molecular Targeted Therapy MeSH
- Mental Disorders drug therapy MeSH
- Imidazoles chemistry pharmacology therapeutic use MeSH
- Clinical Trials as Topic MeSH
- Humans MeSH
- Ligands MeSH
- Neurodegenerative Diseases drug therapy MeSH
- Pyridines chemistry pharmacology therapeutic use MeSH
- Drug Design * MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Imidazoles MeSH
- imidazopyridine MeSH Browser
- Ligands MeSH
- Pyridines MeSH
This article provides an overview of compounds based on imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine, imidazo[4,5-b]pyridine and imidazo[4,5-c]pyridine scaffolds, which act as potent ligands of diverse molecular targets localized in the central nervous system. A literature survey revealed that various imidazopyridines can be powerful modulators of several diseases associated with CNS dysfunction including Alzheimer's disease, Parkinson's disease, schizophrenia, depression or sleeping disorders. A description of target enzymes (e.g., β-secretase, γ-secretase, fatty acid amide hydrolase - FAAH, leucine-rich repeat kinase 2 - LRRK2) and selected receptors (e.g., GABA-A, histamine H3, serotonin 5-HT3, 5-HT4, 5-HT6, dopamine D4, adenosine A2A, orexin), modes of action of imidazopyridine-based ligands and their therapeutic importance is discussed.
References provided by Crossref.org
